Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
Copyright policy )Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
An antibody-drug conjugate targeting LGR5 effectively treats intestinal cancer in preclinical models.
- GENENTECH INC United States
Male, Genes, APC, Time Factors, Dose-Response Relationship, Drug, Immunotoxins, Mice, Nude, Antineoplastic Agents, Mice, Transgenic, Receptors, G-Protein-Coupled, Gene Expression Regulation, Neoplastic, Mice, Inbred C57BL, Rats, Sprague-Dawley, Inhibitory Concentration 50, Cell Line, Tumor, Colonic Neoplasms, Neoplastic Stem Cells, Animals, Feasibility Studies, Female, Cell Proliferation
Male, Genes, APC, Time Factors, Dose-Response Relationship, Drug, Immunotoxins, Mice, Nude, Antineoplastic Agents, Mice, Transgenic, Receptors, G-Protein-Coupled, Gene Expression Regulation, Neoplastic, Mice, Inbred C57BL, Rats, Sprague-Dawley, Inhibitory Concentration 50, Cell Line, Tumor, Colonic Neoplasms, Neoplastic Stem Cells, Animals, Feasibility Studies, Female, Cell Proliferation
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).162 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!